Medtronic's Smart Insulin Management System Gains FDA Approval and Launches for Multi-Daily Injections

Medtronic has achieved a significant milestone with the FDA clearance of its new Smart MDI system, which includes the InPen smart insulin pen and the Simplera continuous glucose monitor (CGM) designed for patients who require multiple daily insulin injections. This system represents an advancement in diabetes management by offering real-time, personalized insulin dosing recommendations based on glucose levels and carbohydrate intake, thus helping mitigate the risk of missed doses and subsequent glucose spikes[1][2]. The InPen, as a reusable insulin pen, sends critical dosing information to a user app, enhancing the accuracy of insulin management routines[1]. Concurrently, the Simplera CGM, a lightweight and disposable monitoring device, integrates seamlessly with the app to improve user blood sugar control by alerting them to potential dose errors[2].